Research & Education

The Implementation of Lung Cancer Screening - The Poland Experience

March 5, 2019 at 1:00PM CET - Recording Available
 Witold_Rzyman  
Jim Mulshine

Witold Rzyman, MD, PHD
Professor
Chief Surgeon
Dept. of Thoracic Surgery
Medical University of Gdańsk, Poland

 James L. Mulshine, MD

Professor
Chair, Screening and Early Detection Committee, IASLC
Rush University, Chicago  

At the last IASLC World Conference on Lung Cancer (WCLC 2018) in Toronto, we learned that the ten year follow-up of the randomized, Dutch/ Belgian low-dose CT screening trial, NELSON, reported significant mortality reduction benefit, confirming the earlier report of the National Lung Screening Trial.

Since then, additional low-dose screening trials from Milan and Japan reported significantly positive mortality outcomes. From the discussions in Toronto, it is clear that a number of other countries are considering implementing lung cancer screening, but there are a number of issues regarding screening implementation that are of concern in various national settings. As a result, the IASLC decided to present examples of screening implementation to enhance understanding of how aspects of management for low-dose CT screening can be best approached.

In this webinar, Professor Witold Ryzman, MD, will share the experience on developing and implementing a pilot program to demonstrate how national screening for lung cancer in Poland can be implemented. Lung cancer screening in Poland is about to begin as a national demonstration project in 2019. The history of four pilot Polish projects that began in 2008 as well as the efforts of building a comprehensive screening centre in Gdańsk as the way to build a final national program will be presented.

DOWNLOAD RECORDING

Attendees can now view IASLC Live webinars via their mobile device.  

Downloading of the Cisco WebEx Meetings app is required.

Once the app is installed on your device you will need to enter the event number for each session.

 Registration is required for all IASLC webinars.